208459-81-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine is used as a pharmaceutical compound for its antihyperglycemic properties, helping to manage and treat diabetes by lowering blood sugar levels. Its effectiveness is comparable to that of Glimepiride, a well-established antihyperglycemic drug.
Used in Oncology:
In the field of oncology, 4-Chloro-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine is used as an antitumor agent. Its pyrrolopyrimidine structure contributes to its potential in targeting and inhibiting the growth of cancer cells, making it a valuable compound in the development of novel cancer treatments.
Used in Antiviral Applications:
4-Chloro-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine is also utilized as an antiviral agent, leveraging its ability to inhibit viral replication and reduce the severity of viral infections. This application makes it a promising candidate for the development of new antiviral drugs to combat various viral diseases.
Overall, 4-Chloro-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine is a versatile compound with significant potential in the pharmaceutical industry, particularly in the development of treatments for diabetes, cancer, and viral infections. Its multifaceted applications highlight the importance of continued research and development in this area to fully realize its therapeutic potential.

References

Mohamed, M. S., et al. "Synthesis and Evaluation of Novel Pyrroles and Pyrrolopyrimidines as Anti-Hyperglycemic Agents." Biomed Research International 2014.1(2014):249780. Babi?, Maja Stipkovi?, et al. "N-1 alkyl, 1, 2, 3-triazolyl and C-5 alkynyl cytosine, uracil an C-6 alkyl pyrrolo [2, 3-d] pyrimidine derivatives: synthesis, cytostatic and antibacterial evaluations." Tetrahedron Symposium Challenges in Biological, Bioorganic, Organic & Medicinal Chemistrysitges, ?panjolska 2016.

Upstream product

• 71-43-2 benzene 
• 98-86-2 acetophenone 
• 70-11-1 α-bromoacetophenone 
• 1032-67-3 N-benzoylmethylphthalimide 
• 1207543-30-3 4‐chloro‐5‐iodo‐7‐((2‐(trimethylsilyl)ethoxy)methyl)‐7H‐pyrrolo[2,3‐d]pyrimidine 
• 54153-51-4 2-amino-3-cyano-4-phenylpyrrole 
• 54760-24-6 2-amino-4-phenyl-1H-pyrrole-3-carboxylic acid amide 
• 871671-45-3 5-phenylpyrrolo-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one 

Downstream Products

• 871671-48-6 7-(5-O-tert-butyldimethylsilyl-2,3-O-isopropylidenyl-β-D-ribofuranosyl)-4-chloro-5-phenylpyrrolo[2,3-d]pyrimidine 
• 871671-47-5 4-chloro-7-(5-deoxy-2,3-O-isopropylidenyl-β-D-ribofuranosyl)-5-phenylpyrrolo[2,3-d]pyrimidine 
• 186393-51-1 4-N-phenylamino-5-phenylpyrrolo[2,3-d]pyrimidine 
• 1610549-28-4 C₁₇H₁₆N₆S 
• 1610549-20-6 1-(3-chlorophenyl)-3-(5-(2-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea 
• 871671-59-9 4-N-(N-cyclopropylcarbamoylmethyl)amino-5-phenyl-7-(5-deoxy-2,3-O-isopropylidenyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 
• 871672-05-8 4-N-(N-cyclopropylthionocarbamoylmethyl)amino-5-phenyl-7-(5-deoxy-2,3-O-isopropylidenyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

MAP4K4 INHIBITORS

This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method of treatmentof cardiac conditions.In particular, the present invention relates to compounds of formula (I):

MAP4K4 INHIBITORS

This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, f

Facile methods for the synthesis of 5-aryl and 5-iodo pyrrolo[2,3-d] pyrimidines

An efficient and environmentally benign one-pot method has been developed for the synthesis of 4-amino-5-arylpyrrolo[2,3-d]pyrimidines. Phthalimido acetophenones were reacted with cyanoacetamide to give 2-amino-4-phenyl-1H- pyrrole-3-carboxamides, which were further converted to 5-aryl-3H-pyrrolo[2,3-d] pyrimidin-4-ones. A novel method is also developed for the synthesis of 4-amino-5-iodopyrrolo[2,3-d]pyrimidines.

Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-β-d-ribofuranosyl) pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds

4-(Phenylamino)-5-phenyl-7-(5-deoxy-β-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine (1) and related compounds known as "diaryltubercidin" analogues are potent inhibitors of adenosine kinase (AK) and are orally active in animal models of pain such as the rat formalin paw model (GP3269 ED 50 = 6.4 mg/kg). However, the utility of this compound class is limited by poor water solubility that can be attributed to the high energy of crystallization caused by stacking of the parallel C4 and C5 aryl rings in the solid state (compound 1 and GP3269 each with pH 7.4 solubility 50 = 3 nM and water solubility = 32 ± 9 μg/mL at pH 7.4), was further characterized in biological assays. Compound 16c exhibited strong oral efficacy in the rat formalin paw model (ED50 of 2.5 mg/kg). In the most advanced assay, 16c was found to inhibit bradykinin-induced licking in marmoset monkeys with an ED50 estimated at 0.9 mg/kg without producing evidence of side effects such as ataxia, sedation, and emesis at this dose. However, lethal toxicity in the rat formalin paw model occurred with high doses of 16c, and further work on this series was discontinued.